Altered DNA methylation of CYP2E1 gene in schizophrenia patients with tardive dyskinesia

Abstract

Background About 20–30% of patients with schizophrenia develop tardive dyskinesia (TD). Oxidative stress is one potential causes of TD. CYP2E1 is considered as an oxidative stress-related gene, however, no study has been reported on the DNA methylation levels of the CYP2E1 in schizophrenia or TD. Methods A total of 35 schizophrenia patients with TD, 35 schizophrenia patients without TD (NTD), and 35 health controls (HCs) were collected in Beijing, China. DNA was extracted from peripheral blood samples. The promoter methylation levels of CYP2E1 were detected using pyrosequencing. The generalized linear model (GLM) was used to examine the methylation levels of three CpG sites among three diagnostic groups (TD vs. NTD vs. HC). Results The average methylation levels were 8.8 ± 10.0, 14.5 ± 11.9 and 15.1 ± 11.3 in TD, NTD and HC groups, respectively. The F-test in GLM revealed overall differences in the average of methylation levels of three CpG sites among three diagnostic groups (p = 0.0227) and in the third CpG site (p = 0.0026). Furthermore, the TD group had lower average methylation levels than HC and NTD groups (p = 0.0115 and 0.0268, respectively). Specifically, TD group showed lower methylation levels in the third CpG site than HC and NTD groups (p = 0.0012 and 0.0072, respectively). Additionally, associations of the methylation levels with clinical features in the TD group were observed using Spearman correlation analysis. Conclusion This study provides the first evidence of DNA methylation levels in the promoter of CYP2E1 gene associated with schizophrenia and TD. The abnormal DNA methylation might serve as a potential mechanism for TD.

Indicators of HSV1 Infection, ECM–Receptor Interaction, and Chromatin Modulation in a Nuclear Family with Schizophrenia

“…CYP2E1 enzyme expression is differently influenced by epigenetic variation such as DNA methylation [ 38 ]. DNA methylation levels in the promoter of the CYP2E1 gene have been associated with SCZ and tardive dyskinesia [ 39 ]. In fact, a Chinese case–control study revealed that two CYP2E1 SNPs were associated with SCZ [ 40 ].…”

DNA Methylation in Alcohol Use Disorder

“…In addition, CYP2E1 is involved in the occurrence and development of neurological diseases. It was found that the low methylation level of CYP2E1 may be related to the underlying mechanism of schizophrenia [ 63 ]. Evaluation of candidate genes by nitrite phosphosequencing in cortical tissue of patients with Parkinson’s disease revealed hypomethylation of CYP2E1 [ 64 ].…”

DNA methylation status of SHATI/NAT8L promoter in the blood of cigarette smokers

“…12,14 Current pyrosequencing technology, applicable to the highthroughput quantification of DNA modifications, is a strong tool for exploring biomarkers of various diseases. 15,16 This method enables the identification of alterations in the methylation status of DNA in the peripheral blood of patients with schizophrenia, 17,18 major depressive disorder (MDD), 19 and bipolar disorder. 20 The methylation levels of the brain-derived neurotrophic factor (BDNF) promoter, measured in the peripheral blood by pyrosequencing, increased in patients with schizophrenia 17 and decreased in those with MDD.…”